Lantheus Holdings (Lantheus Holdings) Interest Expense : $-20 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Lantheus Holdings Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Lantheus Holdings's interest expense for the three months ended in Dec. 2023 was $ -5 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was $-20 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Lantheus Holdings's Operating Income for the three months ended in Dec. 2023 was $ 137 Mil. Lantheus Holdings's Interest Expense for the three months ended in Dec. 2023 was $ -5 Mil. Lantheus Holdings's Interest Coverage for the quarter that ended in Dec. 2023 was 27.27. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lantheus Holdings Interest Expense Historical Data

The historical data trend for Lantheus Holdings's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lantheus Holdings Interest Expense Chart

Lantheus Holdings Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-13.62

-9.48

-7.75

-7.19

-20.02

Lantheus Holdings Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-2.58	-4.99	-4.93	-5.05	-5.04

Lantheus Holdings Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-20 Mil.

Lantheus Holdings (NAS:LNTH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Lantheus Holdings's Interest Expense for the three months ended in Dec. 2023 was $-5 Mil. Its Operating Income for the three months ended in Dec. 2023 was $137 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was $616 Mil.

Lantheus Holdings's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	137.486	/	-5.041
	=	27.27

The higher the ratio, the stronger the company's financial strength is.

Lantheus Holdings (Lantheus Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Lantheus Holdings Inc (NAS:LNTH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

0L8:Germany

Address

201 Burlington Road, South Building, Bedford, MA, USA, 01730

Website

https://www.lantheus.com

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.

Executives

Andrea Sabens	officer: Chief Accounting Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Marshall Robert J. Jr.	officer: CFO and Treasurer	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Paul Blanchfield	officer: Chief Commercial Officer	C/O LANTHEUS HOLDINGS, INC., 331, NORTH BILLERICA MA 01862
Mary Anne Heino	director, officer: CEO and President	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA NY 01862
Daniel Niedzwiecki	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Minnie Baylor-henry	director	C/O SCPHARMACUETICALS, INC., 2400 DISTRICT AVENUE SUITE 310, BURLINGTON MA 01803
Etienne Montagut	officer: See Remarks	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Sam R Leno	director	C/O BOSTON SCIENTIFIC CORPORATION, ONE BOSTON SCIENTIFIC PLACE, NATICK MA 01760
Brian A Markison	director	501 FIFTH STREET, BRISTOL TN 37620
Jean-claude Provost	officer: Chief Medical Officer	C/O LANTHEUS HOLDINGS, INC., 201 BURLINGTON RD, SOUTH BUILDING, BEDFORD MA 01730
Julie Mchugh	director	C/O IRONWOOD PHARMACEUTICALS, INC., 100 SUMMER STREET, SUITE 2300, BOSTON MA 02110
Gerard Ber	director	C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169
Carol Walker	officer: Senior Vice President, Quality	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
Ying Vivian Yao	officer: Chief Human Resources Officer	C/O LANTHEUS HOLDINGS, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862
John J. Bolla	director	C/O LANTHEUS MEDICAL IMAGING, INC., 331 TREBLE COVE ROAD, NORTH BILLERICA MA 01862